Industry
Biotechnology
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
April 03, 2024 | 12:17 pm
Portfolio Pulse from Benzinga Insights
March 14, 2024 | 9:33 pm
Portfolio Pulse from Avi Kapoor
February 22, 2024 | 6:38 pm
Portfolio Pulse from Benzinga Insights
February 22, 2024 | 5:31 pm
Portfolio Pulse from Avi Kapoor
February 22, 2024 | 12:55 pm
Portfolio Pulse from Benzinga Insights
February 21, 2024 | 9:31 pm
Portfolio Pulse from Benzinga Newsdesk
February 21, 2024 | 8:58 pm
Portfolio Pulse from Benzinga Insights
January 31, 2024 | 5:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.